A systematic review of neuroimaging studies of adults aged 35 and older with clinical, symptomatic and genetic risk for attention-deficit/hyperactivity disorder.

Dialogues Clin NeurosciJul 19, 2026 (epub)
Clinical ResearchNeurologyPsychiatryOpen access

Natalia G Docteur, Hayley G P Huston, Avery A Krupa et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined neuroimaging studies of adults aged 35 and older with clinical, symptomatic, or genetic risk for ADHD. It found that ADHD groups showed significant brain alterations in fronto-striatal, fronto-parietal, and limbic systems compared to controls. Most studies included had a low risk of bias, with 11 out of 13 meeting this criterion.

Key findings

  • ADHD groups exhibited alterations in fronto-striatal, fronto-parietal, and limbic systems compared to controls.
  • Middle-aged adults with clinical ADHD showed more widespread cortical structural differences.
  • Older adults with ADHD demonstrated abnormalities primarily in frontal regions.
  • Interactions were noted between genetic risk for ADHD and Alzheimer's disease-related pathology.

Why it matters

Understanding the neurobiological mechanisms of ADHD in older adults is crucial, as it may inform strategies for managing cognitive decline and dementia risk associated with the disorder.

Source

PubMed · PMID 42472451Free full text on PubMed Central

Published in Dialogues Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.